Posted in | News | Nanomaterials

Nanocomposite Coating Developer MesoCoat Receives Recognition from the U.S. Army

Abakan Inc.'s management is pleased to announce that the U.S. Army has recognized MesoCoat, Inc., an Abakan portfolio company, as one of the most successful companies in the Small Business Innovation Research (SBIR) program.

SBIR was established by Congress to provide small businesses and research institutions with opportunities to participate in government sponsored research and development. Success within the SBIR program is measured over three highly competitive phases selecting the best companies and teams developing and commercializing cutting edge technologies. MesoCoat has been singled out among SBIR awardees as an SBIR success story for its progress in attracting funding and customers from the private sector and non-SBIR government sources to transition its PComP(TM) nanocomposite cermet coating technology into viable commercial products and savings for the U.S. Department of Defense (DoD).

The U.S. Military spends an estimated $40 billion each year to address wear and corrosion issues associated with military equipment. Consequently, the U.S. Army, along with other branches of the U.S. military, is constantly searching for investment opportunities in the best new material science solutions. "Our investment in MesoCoat is further validated by the U.S. Army report which expressed considerable interest in the PComP(TM) nano-composite spray powder product line," according to Robert Miller, Abakan's CEO. "The Department of Defense could represent a multibillion dollar market for the application of MesoCoat products."

  "Coating solutions provided by MesoCoat's technology would
    directly reduce the cost of corrosion. MesoCoat's PComP(TM)
    technology can enhance wear and corrosion resistance, along with
    reducing spallation in a variety of applications including
    aircraft materials, landing gears, rail guns, bearings, military
    vehicles, and ship structures. The nanocomposite materials will
    replace chrome plating for repairing F-22, F-15, F-16, and F-35
    aircraft since DoD has restricted use of chrome plating and no
    acceptable substitute exists for joint fighters. Funds from a DoD
    program to develop thermal barrier and chrome replacement coatings
    have assisted MesoCoat with the development of environmentally
    safe, superior performance coatings that would eliminate the use
    of toxic and carcinogenic compounds and processes currently being
    used for coating many metal structures."

The PComP(TM) nano-composite cermet thermal spray coating product line is intended to replace chrome plating for repairing and extending the service life of F-22, F-15, F-16 and F-35 aircraft and other DoD systems as the use of chrome plating has been restricted. MesoCoat is currently working with the Air Forces' Propulsion Environmental Working Group, General Dynamics, and others to speed transition of the DoD to the higher performance, higher productivity PComP(TM) alternative. Andrew Sherman, MesoCoat's CEO stated that "The Department of Defense and commercial industry now have a replacement for hexavalent chromium that is affordable, very environmentally friendly, and superior to the materials it replaces."

Concern over the use of hazardous materials has led to legislation related to the use of certain toxic materials, including chrome plating. The hexavalent chrome replacement market by itself represents a $3 billion plus market opportunity for firms armed with acceptable alternatives. According to Curtis Glasgow, GM of MesoCoat's PComP(TM) product line, "Companies not only have to be able to engineer new materials with appropriate properties that meet testing criteria to replace hexavalent chrome, they also have to be able to apply that material to part surfaces. We have spent the last year building and refining that capability to deliver a superior yet cost-effective product to the market place."

Source: http://www.mesocoat.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.